Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia.

By L. Sehn, J. Donaldson, M. Chhanabhai, C. Fitzgerald, Karamjit K. Gill, R. Klasa, N. Macpherson, S. O'Reilly, J. Spinelli, J. Sutherland and 3 more. Journal of Clinical Oncology, 2005

1,048 citations recorded by the source corpus.

Subfields: Neurology, Pathology and Forensic Medicine, Public Health, Environmental and Occupational Health

View Paper: https://www.semanticscholar.org/paper/66a05701b26013559235227af30abb1d560166e9

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. A. Ng

Citations in the corpus

• Diffuse large B-cell lymphoma. (2007, result): “In a population-based analysis, the impressive efficacy results of the GELA trial can be repeated because the safety results are confirmed [ 10 ]: outcomes for patients with DLBCL were compared between two periods, CHOP (old) and R-CHOP (new) treatment recommendations.”